ESLA

Estrella is a clinical-stage cell-therapy company with no product, no revenue, and one lead candidate (EB103, CD19 ARTEMIS T-cell) in a Phase I/II trial with just nine patients dosed as of 12/31/25. The MD&A is explicit that it has 'not generated any revenue from product sales,' does not expect to 'for the foreseeable future,' and expects net losses to 'increase substantially' as EB103 advances. That is the entire investment case: a binary, years-out clinical readout funded by capital the company does not currently have.

The balance sheet is the disqualifier. Stockholders' equity is NEGATIVE $10.4M (liabilities/equity of -1.31x), driven by total liabilities exploding +351.9% to $13.5M — almost entirely the ~$12.4M of related-party milestone liabilities accrued to Eureka, its licensor and trial-services provider. Against that sits $1.38M of cash and $1.68M of current assets versus $13.5M of current liabilities: a current ratio near 0.12. The FY2025 net loss was $13.1M and the accumulated deficit is $37.0M. Even with operating cash outflow of only $1.79M (flattered by unpaid accrued liabilities, not real solvency), the company plainly cannot fund the 'substantial additional funds' the risk factors say it needs. This is a going-concern-shaped situation dependent on continuous, dilutive financing — shares already grew +17.9% and a May–Sept 2025 private placement was needed to keep the lights on.